Quote | Brickell Biotech Inc. (NYSE:BBI)
Last: | $ |
---|---|
Change Percent: | -4.38% |
Open: | $1.14 |
Close: | $1.09 |
High: | $1.18 |
Low: | $1.09 |
Volume: | 93,157 |
Last Trade Date Time: | 02/12/2020 04:43:14 pm |
News | Brickell Biotech Inc. (NYSE:BBI)
Clinical-stage biotech Brickell Biotech, Inc. ( NASDAQ: BBI ) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc. Accordingly, the company said that BBI’s name, logo, website, and branding would chan...
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Message Board Posts | Brickell Biotech Inc. (NYSE:BBI)
Subject | By | Source | When |
---|---|---|---|
JUST IN: $BBI Brickell Biotech Announces Launch Date | whytestocks | investorshub | 11/18/2020 10:45:17 PM |
BREAKING NEWS: $BBI Are These Penny Stocks To | whytestocks | investorshub | 08/28/2020 8:00:13 PM |
fly Blackbird fly | Spruitenburg | investorshub | 04/17/2018 12:20:59 PM |
Starting to look good | Rampage123 | investorshub | 11/11/2017 3:25:50 PM |
1,25M Volume. Not that bad. | Peron | investorshub | 03/08/2016 3:19:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Brickell Biotech Inc. Company Name:
BBI Stock Symbol:
NYSE Market:
New name, logo, website, and branding reflect the Company’s strategic shift toward developing potentially groundbreaking autoimmune and inflammatory disease therapies Company to begin trading under new ticker symbol “FRTX” on September 8, 2022 Compan...
Phase 1 study of BBI-02 progressing well and expect to initiate MAD part of the study next month On track to report SAD and MAD topline results from BBI-02 Phase 1 study by early 2023 Development of BBI-10 and next-generation kinase inhibitors advancing through early precl...
BOULDER, Colo., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company striving to transform patient lives by developing innovative and differentiated prescription therapeutics for the treatment of autoi...